PHARMA LITERATI

NMIMS, Pharmacy, Mumbai is organizing Workshop on Awareness of Indian Pharmacopoeia and Indian Pharmacopoeia Reference Standards (IPRS). The details for the same are as follows: Theme:      Workshop on Awareness of Indian Pharmacopoeia and Indian Pharmacopoeia Reference Standards (IPRS)    Dates:             7th October 2015. Organized by:   SVKM's NMIMS.  Location:           Mumbai. Details available at:   http://pharmacy.nmims.edu/docs/workshop-agenda.pdf

A new book on "Active Pharmaceutical Ingredient (API) Technology" has been published recently. This book is as per 2015 Semester pattern (Semester V) of Savitribai Phule Pune University The details for the same are as follows: Author:                       Dr. Anwar Shaikh. Publishers:                 Knowledge Publications, Nashik

Vivekananda College of Pharmacy and Ayurvidye Trust will jointly hold a one-day course on Smileys to Scientific Writing. The details for the same are as follows: Theme:             Smileys to Scientific Writing Dates:               November 27, 2015 . Location:            Vivekananda College of Pharmacy, Rajajinagar in Bengaluru. http://www.pharmabiz.com/Services/ProjectTenders/TendersDetails.aspx?aid=90821&sid=15

NMIMS, Pharmacy, Mumbai is organizing "National conference on nanotechnology in drug delivery research: Innovations, challenges & opportunities". The details for the same are as follows: Theme:       National conference on nanotechnology in drug delivery research: Innovations, challenges & opportunities.           Dates:              16th-17th October 2015 . Organized by:     ICMR and SVKM's NMIMS.   Location:             Mumbai. Details available at:   http://pharmacy.nmims.edu/docs/ncnddr.pdf

Every week of thousands of patent applications are published in India. The  patent applications filed by the pharma academic research institutes in India  go un-noticed. We publish a list of Indian applications published related to pharma academics. This would provide us an idea about the kind of academic research being carried out in these institutes. For details of these patents, please write back to us at  pharmaliterati@gmail.com Invention Application No Inventors Institute Anti-carcinogenic embryonic antigens activity of elaeocarpus 784/DEL/2014 A 1) Dr. Dinesh Kumar Garg Not known Monoclonal antibody specific for shigella flexneri and...

Times of India reports that Asia's largest vaccine maker, Pune-based Serum Institute will develop a biologic drug to treat all four strains of the dengue virus, and is in the process of applying to the Ministry of Science and Technology for a "fast-track approval" to roll-out the treatment in the country. Serum, which has tied up with US-based biotechnology company Visterra to use its technology to develop the monoclonal antibody, hopes to commercialize the treatment within 12-18 months of getting the regulatory approvals, Serum Institute CEO Adar Poonawalla told TOI. The biologic treatment (monoclonal anti-body) once rolled out will be given as an injection to cure dengue, and cost between Rs 5,000-10,000 for a single dose. Only one dose will be required. While Serum's biologic drug could become one of the first treatments to roll out, other biggies like Sanofi and Novartis are also in the race to launch a vaccine may happen over the next few years. If t...

At present, there is no specific approved vaccine or therapy to prevent dengue fever. But now a Bengaluru-based lab has come up with a tablet to treat the dreaded vector-borne disease. Bengaluru-based Micro Labs Ltd has recently launched a botanical pill 'Caripill' that helps to increase the platelet count in dengue patients. The drug, which has been approved by the scientific and regulatory authority, is made from Carica Papaya leaf extract and reportedly does not have any side-effects. The pill has been proven to be safe and effective in about one lakh patients across the country. The lab claims that the drug, which underwent clinical trials on 250 patients, has shown positive results with a dramatic decrease in the haemorrhage condition. Besides, none of the patients had to undergo blood transfusion so far. It is believed that Caripill is the first drug to be backed by adequate scientific data to increase the platelet count in dengue cases. Since the...

The medical community in USA is outraged by a 5,500 percent price hike for Daraprim® , after a big New York based pharmaceutical company purchased the patent for it. The drug has been on the market for over 60 years, and can be essential to certain AIDS and cancer treatments. The New York-based Turing Pharmaceuticals raised the price of Daraprim®, from $13.50 to $750 per pill in just over a month after buying the rights for the drug from Impax Laboratories. The drug is used to treat toxoplasmosis, the second most common food-borne disease that affects patients suffering from AIDS and cancer. It has been produced since 1953 and is on the WHO List of Essential Medicines. But now medical associations are beating their drums about the sudden price hike and potential affordability of Daraprim®, as a treatment. Please see: ·   http://www.rt.com/usa/316046-pharma-daraprim-price-hike/ ·   http://motherboard.vice.com/read/when-drug-startups-make-big-pharma-look-lik...

The Economic Times reports that Sun Pharmaceutical Industries Ltd is selling erstwhile Ranbaxy's two divisions in central nervous system (CNS) segment in India to Strides Arcolab for Rs 165 crore. Sun Pharma and Strides have entered into a definitive agreement related to erstwhile Ranbaxy's 'Solus' and 'Solus Care' divisions operating in the central nervous system (CNS) segment in India, the company said in a statement.   The agreement involves transfer of these two marketing divisions, along with employees to Strides for a consideration of Rs 165 crore, it added. Commenting on the development, Sun Pharma CEO-India Business Abhay Gandhi said, "We have evaluated each and every therapy segment that we are present in and how these businesses can grow going forward. Based on this evaluation, we firmly believe that the potential of Solus and Solus Care divisions can be greatly enhanced with the focus that Strides will put in growing them. The divestment w...

The Education division of Indian Pharmaceutical Association (IPA) has announced the National Elocution Competition for the year 2015.  Please see the details: http://www.ipapharma.org/news/NEC%202015.pdf The competition is divided into four rounds: Round Preliminary State Semi-final Final Duration and timing Duration and timing will be fixed by the head of the institution Duration and timing will be fixed by the State Coordinator Duration and timing will be fixed by the Convener, NEC-2015 Duration and timing will be fixed by the Convener, NEC-2015 Judges 3 judges amongst teaching staff to be appointed by Head of Institution where competition is to be conducted. 3 judges to be appointed by the State Coordinator of respective state where competition is to be conducted. 5 judges to be appointed by the Convener, NEC-2015. ...